CSBio CSBio

X
[{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto\u2019s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Galecto"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 consortium","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"ExpreS2ion Biotechnologies"},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AJ Vaccines To Develop Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"AJ Vaccines"},{"orgOrder":0,"company":"Bactolife","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bactolife Receives USD 5 Million in New Funding to Address Gastrointestinal Infections Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bactolife"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Bactolife™ uses its proprietary Binding Protein™ technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance development as well as the general burden of infectious diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding August 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Patients with COVID-19 were able to inhale GB0139 and achieve consistent exposure of GB0139 at levels previously associated with systemic biomarker responses in IPF patients (including YKL-40 and PAI-1).

            Lead Product(s): Olitigaltin

            Therapeutic Area: Infections and Infectious Diseases Product Name: GB0139

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial.

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: The EU Horizon 2020 consortium

            Deal Size: $0.9 million Upfront Cash: Undisclosed

            Deal Type: Funding March 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021.

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY